AGIO · Agios Pharmaceuticals Inc
United States · RS rating 26 · As of 2026-10-14
| Price | 30.97 USD |
|---|---|
| 1-day change | +2.5% |
| RS rating (overall / 1M / 3M / 12M) | 26 / 35 / 19 / 24 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 34 / 36 / 6 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +0.0% |
| Sales growth Q/Q | +55.0% |
| Distance from 52-week high | +31.9% |
| Market cap (USD) | $1.5B |